Challenges to the validity of the “Patent Cooperation Treaty joint applicant” have been a problem for many applicants at the European Patent Office. On October 10, 2023, the EPO’s highest authority, the Enlarged Board of...more
Only U.S. Patent No. 7, 598, 083 (“the ‘083 patent”) remains at issue in Janssen’s suit against Celltrion and Hospira in the District of Massachusetts (C.A. No. 1:15-cv-10698) relating to a biosimilar of Janssen’s Remicade®...more